WaveMan
WaveMan · Company
NKTX · Nkarta, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

NKTX Nkarta (NKTX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001787400
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
77
13F, latest reported quarter

What the filings say about NKTX

Insiders, 180 days
-$4.8K net sold
1 seller · 0% of sales under a 10b5-1 plan

Nkarta insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Nkarta, Inc. insiders sold a net $4.8K of stock across 60 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
HASTINGS PAUL J
Chief Executive Officer
SELL
2026-06-22 SECtraded 2026-06-18
1,776
$4.8K
-39.6%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Jan 15, 2026.
  • The trade is 0.5% of the 390,247 shares held after it.
  • No other insider sold within 30 days.
  • 77 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer HASTINGS PAUL J sold about $4.8K of NKTX on Jun 18, 2026; 77 funds added in the latest 13F quarter.
HASTINGS PAUL J
Chief Executive Officer
SELL
2026-01-20 SECtraded 2026-01-15
26,046
$53.9K
-16.8%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Jun 18, 2025.
  • The trade is 6.7% of the 390,023 shares held after it.
  • 1 other insider sold within 30 days.
  • 77 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer HASTINGS PAUL J sold about $53.9K of NKTX on Jan 15, 2026, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 77 funds added in the latest 13F quarter.
Mahmood Nadir
President
SELL
2026-01-20 SECtraded 2026-01-15
5,649
$11.7K
-16.8%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jun 20, 2023.
  • The trade is 3.4% of the 167,727 shares held after it.
  • 1 other insider sold within 30 days.
  • 77 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President Mahmood Nadir sold about $11.7K of NKTX on Jan 15, 2026, the largest insider sale at the company since 2025; 1 other insider sold within 30 days and 77 funds added in the latest 13F quarter.
HASTINGS PAUL J
Chief Executive Officer
SELL
2025-06-20 SECtraded 2025-06-18
1,790
$3.2K
+4.9%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Jan 15, 2025.
  • The trade is 0.6% of the 320,069 shares held after it.
  • No other insider sold within 30 days.
  • 77 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer HASTINGS PAUL J sold about $3.2K of NKTX on Jun 18, 2025; 77 funds added in the latest 13F quarter.
Shook David
See Remarks
SELL
2025-01-17 SECtraded 2025-01-15
8,638
$19.0K
-25.0%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jun 18, 2024.
  • The trade is 4.5% of the 190,955 shares held after it.
  • 4 other insiders sold within 30 days.
  • 77 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Shook David sold about $19.0K of NKTX on Jan 15, 2025; 4 other insiders sold within 30 days and 77 funds added in the latest 13F quarter.
60 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 55 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$4.8K over 180 days
more than 62% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
77 funds bought in last quarter
more than 59% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
5.7% of the float short (float per yahoo 2026-10-27) · 4.9 days to cover · settled 2026-10-15
more than 50% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch NKTX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-19.0%12M
-23%+5%+34%+62%2025-102025-122026-022026-042026-062026-082026-10 2026-01-15 · HASTINGS PAUL J sold $53.9K2026-01-15 · Mahmood Nadir sold $11.7K2026-06-18 · HASTINGS PAUL J sold $4.8K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NKTX: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
10,805,129 sh
$30.6M
BlackRock, Inc.
6,300,212 sh
$17.8M
NEA Management Company, LLC
3,568,781 sh
$10.1M
SAMSARA BIOCAPITAL, LLC
3,507,666 sh
$9.9M
SR One Capital Management, LP
3,333,333 sh
$9.4M

Congress trades in NKTX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

NKTX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

NKTX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Wasatch Ultra Growth Fund
$4.2M position · as of 2026-06-30
0.9%
Wasatch Long/Short Alpha Fund
$162.6K position · as of 2026-06-30
0.4%
Ultra-Small Company Market Fund
$311.3K position · as of 2026-06-30
0.2%
BlackRock Advantage Small Cap Growth Fund
$746.6K position · as of 2026-06-30
0.1%
AVIP BlackRock Advantage Small Cap Growth Portfolio
$72.7K position · as of 2026-06-30
0.1%
BlackRock Advantage SMID Cap V.I. Fund
$84.4K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
2 active
2
Multi-phase
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $4.8K sold by insiders over 180 days, 77 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

NKTX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$93.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-38.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-29.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-35.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-71.6%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$0n/an/a
Operating income-$122.0M-$128.2M-$131.7M-$119.0M
Net income-$104.1M-$108.8M-$117.5M-$113.8M
EPS (diluted)-1.41-1.60-2.40-2.61
Operating cash flow-$88.7M-$99.7M-$86.2M-$57.0M
Cash$39.6M$27.9M$31.0M$37.5M
SEC XBRL, fiscal years, as known on 2026-10-28

NKTX Stock Sonar score 4/7 axes

Find similar shapesCompare

NKTX ranks highest on risk and compliance (64th percentile) and profitability (62nd), and lowest on insider conviction (30th), among Pharma & Biotech peers.

Profitability
62
Inputs
  • Return on equity-38.8% · 62 pct, sector of 545
  • Return on assets-29.9% · 61 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-35.6% · 65 pct, sector of 576
Insider conviction
30
Inputs
  • Net Form 4 buying (codes P and S), 180d-$5K · 60 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
59
Inputs
  • Funds adding, latest quarter77 · 59 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
64
Inputs
  • Short interest, % of float+5.7% · 55 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+6.8% · 73 pct, sector of 511
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

NKTX filings, in plain words

Are Nkarta insiders buying or selling NKTX?

In the 180 days to 2026-10-28, Nkarta insiders were net sellers, a net $4.8K across purchases and sales reported on Form 4, by 1 seller.

Read the full summary

In the 180 days to 2026-10-28, Nkarta insiders were net sellers of NKTX, a net $4.8K across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies